(Total Views: 41)
Posted On: 12/20/2024 1:37:57 PM
Post# of 273254
$MNMD MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
https://www.businesswire.com/news/home/20241216046321/en/
MindMed to Be Added to the Nasdaq Biotechnology Index
https://www.businesswire.com/news/home/20241219955108/en/
Corporate Presentation December 2024
https://d1io3yog0oux5.cloudfront.net/_80b2b06...+2024+.pdf
https://www.businesswire.com/news/home/20241216046321/en/
MindMed to Be Added to the Nasdaq Biotechnology Index
https://www.businesswire.com/news/home/20241219955108/en/
Corporate Presentation December 2024
https://d1io3yog0oux5.cloudfront.net/_80b2b06...+2024+.pdf
(0)
(0)Scroll down for more posts ▼
